Marcelo Lancellotti

Prof. Dr. Marcelo Lancellotti

Faculty of Pharmaceutical Sciences, Univeristy of Campinas, Campinas, São Paulo 13083-871, Brazil

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MMMarcel Franco Mougenot
Marcel Franco Mougenot
VPVanessa Sousa Pereira
Vanessa Sousa Pereira
ACAna Letícia Rodrigues Costa
Ana Letícia Rodrigues Costa
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
MPMarimelia Porcionatto
Marimelia Porcionatto
Lucimara de la TorreLucimara de la Torre
Lucimara de la Torre
Despite all the progress in the field of liposomes and nanoparticles for applications as drug and gene delivery systems, the specific targeting and immune system escape capabilities of these systems are still limited. Biomimetic nanovesicles emerged as a strategy to overcome these and other limitations associated with synthetic carriers, such as short circulation time, cytotoxicity, and difficulty in crossing biological barriers, since many of the desirable abilities of drug delivery systems are innate characteristics of biological vesicles. Thus, the question arises: would biomimetic nanovesicles be responsible for addressing these advances? It is currently known that biomimetic nanovesicles (BNV) can combine the intrinsic advantages of natural materials with the well-known production methods and controllability of synthetic systems. Besides, the development of the biotechnology and nanotechnology fields has provided a better understanding of the functionalities of biological vesicles and the means for the design and production of biomimetic nanovesicles (BNV). Based on this, this work will focus on tracking the main research on biomimetic nanovesicles (BNV) applied as drug and gene delivery systems, and for vaccines applications. In addition, it will describe the different sources of natural vesicles, the technical perspectives on obtaining them, and the possibility of their hybridization with synthetic liposomes.

29 May 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PMPaula Martins
Paula Martins
DMDaisy Machado
Daisy Machado
TTThais Holtz Theizen
Thais Holtz Theizen
JGJoão Paulo Oliveira Guarnieri
João Paulo Oliveira Guarnieri
BBBruno Gaia Bernardes
Bruno Gaia Bernardes
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
The increase of Zika virus (ZIKV) infections in Brazil in the last two years leaves a prophylactic measures on alert for this new and emerging pathogen. Concerning of our positive experience, we developed a new prototype using Neisseria meningitidis outer membrane vesicles (OMV) on ZIKV cell growth in a fusion of OMV in the envelope of virus particles. The fusion of nanoparticles resulting from outer membrane vesicles of N. meningitidis with infected C6/36 cells line were analyzed by Nano tracking analysis (NTA), zeta potential, differential light scattering (DLS), scan and scanning transmission eletronic microscopy (SEM and STEM) and high resolution mass spectometry (HRMS) for nanostructure characterization. Also, the vaccination effects were viewed by immune response in mice protocols immunization (ELISA and inflammatory chemokines) confirmed by Zika virus soroneutralization test. The results of immunizations in mice showed that antibody production had a titer greater than 1:160 as compared to unvaccinated mice. The immune response of the adjuvant and non-adjuvant formulation activated the cellular immune response TH1 and TH2. In addition, the serum neutralization was able to prevent infection of virus particles in the glial tumor cell model (M059J). This research shows efficient strategies without recombinant technology or DNA vaccines.

Verified
Journal Article
Open access
PDF file
José Rafael de AlmeidaJosé Rafael de Almeida
José Rafael de Almeida
BMBruno Mendes
Bruno Mendes
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
GFGilberto C. Franchi
Gilberto C. Franchi
ÓPÓscar Passos
Óscar Passos
SSSaulo Silva
Saulo Silva
The membrane-active nature of phospholipase A2-derived peptides makes them potential candidates for antineoplastic and antibacterial therapies. Two short 13-mer C-terminal fragments taken from snake venom Lys49-PLA2 toxins (p-AppK and p-Acl), differing by a leucine/phenylalanine substitution, were synthesized and their bioactivity was evaluated. Their capacity to interfere with the survival of Gram-positive and Gram-negative bacteria as well as with solid and liquid tumors was assessed in vitro. Toxicity to red blood cells was investigated via in silico and in vitro techniques. The mode of action was mainly studied by molecular dynamics simulations and membrane permeabilization assays. Briefly, both peptides have dual activity, i.e., they act against both bacteria, including multidrug-resistant strains and tumor cells. All tested bacteria were susceptible to both peptides, Pseudomonas aeruginosa being the most affected. RAMOS, K562, NB4, and CEM cells were the main leukemic targets of the peptides. In general, p-Acl showed more significant activity, suggesting that phenylalanine confers advantages to the antibacterial and antitumor mechanism, particularly for osteosarcoma lines (HOS and MG63). Peptide-based treatment increased the uptake of a DNA-intercalating dye by bacteria, suggesting membrane damage. Indeed, p-AppK and p-Acl did not disrupt erythrocyte membranes, in agreement with in silico predictions. The latter revealed that the peptides deform the membrane and increase its permeability by facilitating solvent penetration. This phenomenon is expected to catalyze the permeation of solutes that otherwise could not cross the hydrophobic membrane core. In conclusion, the present study highlights the role of a single amino acid substitution present in natural sequences towards the development of dual-action agents. In other words, dissecting and fine-tuning biomembrane remodeling proteins, such as snake venom phospholipase A2 isoforms, is again demonstrated as a valuable source of therapeutic peptides.

5 September 2016 in BioMed Research International
Verified
Journal Article
Open access
PDF file
DADanilo Antonini Alves
Danilo Antonini Alves
DMDaisy Machado
Daisy Machado
AMAdriana Melo
Adriana Melo
RPRafaella Fabiana Carneiro Pereira
Rafaella Fabiana Carneiro Pereira
Patricia SeverinoPatricia Severino
Patricia Severino
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is the levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and specifically inhibit the synthesis of bacterial DNA. Levofloxacin hasin vitroactivity against a broad range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic® F127) and levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature. Thus, the aim of the present work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial resistance. Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which form spontaneously from amphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres showed efficiency and enhancement of antimicrobial activity againstEscherichia coli,Pseudomonas aeruginosa, andKlebsiella pneumoniaewhen compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage. In conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal inhibitory concentration of the studied bacterial multiresistance strains. In the future, this new formulation will be used after being tested in animal models in patients with resistant bacterial strains.

22 September 2025 in Pathogens
Verified
Journal Article
Open access
PDF file
FUFlora Miranda Ulgheri
Flora Miranda Ulgheri
BBBruno Gaia Bernardes
Bruno Gaia Bernardes
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
Dengue, caused by the dengue virus (DENV), is rapidly expanding its geographical footprint, with increasing incidence not only in over 100 endemic countries in the southern hemisphere but also with more autochthonous transmissions now reported in the northern hemisphere, including regions of Europe and the United States. The clinical presentation of DENV infection ranges from mild febrile illness to severe and potentially fatal conditions, such as dengue hemorrhagic fever (DHF), dengue shock syndrome (DSS), and diverse neurological complications. While vaccine development efforts are underway, significant challenges remain, underscoring the urgent need for a deeper understanding of the virus. This urgency is particularly palpable in Brazil, which has faced an unprecedented surge in dengue cases during the 2024–2025 period. The country has recorded an alarmingly high number of infections and related deaths, stretching its public health infrastructure and highlighting the complex interplay of climate change, urbanization, and viral dynamics in disease propagation. This review provides a global perspective on dengue, systematically exploring its history, morphology, viral cycle, pathogenesis, and epidemiology. By integrating these critical aspects, this article aims to identify pivotal knowledge gaps and guide future research directions essential for developing improved public health interventions against this complex and evolving disease.

25 July 2011 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
LHLuciana Maria De Hollanda
Luciana Maria De Hollanda
GCGisele Cg Cury
Gisele Cg Cury
RPRafaella Fc Pereira
Rafaella Fc Pereira
GAGracielle Ferreira Andrade
Gracielle Ferreira Andrade
ASAndreza Sousa
Andreza Sousa
Marcelo LancellottiMarcelo Lancellotti
Marcelo Lancellotti
Background: This study aimed the use of mesoporous silica under the naturally transformable Neisseria meningitidis, an important pathogen implicated in the genetic horizontal transfer of DNA causing a escape of the principal vaccination measures worldwide by the capsular switching process. This study verified the effects of mesoporous silica under N. meningitidis transformation specifically under the capsular replacement. Methods: we used three different mesoporous silica particles to verify their action in N. meningitis transformation frequency. Results: we verified the increase in the capsular gene replacement of this bacterium with the three mesoporous silica nanoparticles. Conclusion: the mesouporous silica particles were capable of increasing the capsule replacement frequency in N. meningitidis.